Source: Since its massive Pfizer merger fell through last year, Allergan has persisted with “stepping-stone deals” rather than a transformational buy. Monday, the drugmaker unveiled its latest buy, Zeltiq, a $2.47 billion add-on for its aesthetics business. With Zeltiq, Allergan will get the sales leader in body contouring—read fat-fighting—and a…...